Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy of two antidepressant medications, bupropion and citalopram. Bupropion is an aminoketone class antidepressant that primarily inhibits the reuptake of norepinephrine and dopamine, thereby increasing their levels in the brain. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels by inhibiting its reuptake into presynaptic neurons. The combination is used off-label for treatment-resistant depression when monotherapy with either agent has been insufficient. Clinical studies suggest this combination can be more effective than switching to monotherapy in patients who have not responded to initial treatment[1][7]. Both drugs are taken orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupropion + citalopram.